The present invention relates to an mRNA construct containing 5'-UTR with improved translation efficiency and a vaccine composition comprising same, and more particularly to an mRNA construct containing 5'-UTR with improved translation efficiency that have been engineered to include specific motifs, a codon-optimized signal sequence and an antigen encoding sequence, and a vaccine composition comprising the same. The mRNA construct according to the present invention contains a 5'-UTR with improved translation efficiency, which can effectively induce the expression of an antigenic polypeptide and is useful for vaccine development as it can be expected to increase immunogenicity as a vaccine.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
2.
NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST GLUCOSYLCERAMIDE SYNTHASE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESSES FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
Provided are a compound having an inhibitory activity against glucosylceramide synthase (GCS), i.e., compounds having a 2,3-dihydro-1H-indene, 1,2,3,4-tetrahydronaphthalene, or chromane moiety, or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof, wherein the compound or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and exhibits the effects of alleviating symptoms in the central nervous system as well as in the peripheral nervous system, through excellent blood-brain barrier permeability, and therefore, the compound or pharmaceutically acceptable salt thereof can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
C07D 453/02 - Composés hétérocycliques contenant des systèmes cycliques quinuclidine ou isoquinuclidine, p. ex. alcaloïdes de la quinine contenant des systèmes cycliques quinuclidine sans autre condensation
A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p. ex. quinuclidine
3.
NOVEL LIQUID FORMULATION FOR PREVENTION OR TREATMENT OF THROMBOTIC DISEASE
The present invention relates to a pharmaceutical formulation composition of plasma proteins, specifically ADAMTS13 proteins, variants thereof, and functional fragments thereof, and a composition containing same for the prevention or treatment of a thrombotic disease. The composition of the present invention not only efficiently evades typical autoantibodies known to have high binding affinity for the main domain of ADAMTS-13, but also has an efficient combination of formulation ingredients that enables maintaining high levels of colloidal stability, refrigeration stability, purity, and aggregation inhibition for an extended period. In addition, the therapeutically effective amount of the composition of the present invention is significantly lower than those of commercially available enzyme replacement treatments, and thus the present invention can be used as an efficient treatment having patient compliance level and safety suitable for long-term administration.
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
The present invention relates to a pharmaceutical composition for preventing or treating hemarthrosis, which exhibits an excellent therapeutic effect against hemarthrosis and comprises: an anti-TFPI antibody; and a hyaluronic acid or a pharmaceutically acceptable salt thereof, wherein the hyaluronic acid or pharmaceutically acceptable salt thereof is sodium hyaluronate crosslinked with 1,4-butanediol diglycidyl ether (BDDE).
A pharmaceutical composition capable of exhibiting excellent efficacy against hemathrosis by including an anti-TFPI antibody and hyaluronic acid. A use of the pharmaceutical composition is also disclosed. A method for preventing or treating hemathrosis in a subject in need thereof, includes administering to the subject an effective amount of a pharmaceutical composition comprising an anti-TFPI antibody and hyaluronic acid.
A composition and a use thereof in treating facial dysmorphism in mucopolysaccharidosis are disclosed. The composition is obtained by subcutaneously injecting a composition into the face for facial subcutaneous injection formulation including a lysosomal enzyme and hyaluronic acid into a subject, thereby effectively improving facial dysmorphism in mucopolysaccharidosis
The present invention relates to a composition for the treatment of facial dysmorphism in mucopolysaccharidosis, and a method of treatment therefor, wherein a composition of a facial subcutaneous injection formulation comprising lysosomal enzymes and hyaluronic acid can be subcutaneously injected into a subject's face to effectively ameliorate facial dysmorphism in mucopolysaccharidosis.
The present invention relates to a pharmaceutical composition of a high concentration of heparan N-sulfatase (HNS) with enhanced stability for CNS delivery and a pharmaceutical formulation comprising the same. The pharmaceutical composition and pharmaceutical formulation comprising the same according to the present invention have excellent formulation stability, such as a reduction in turbidity and a significant improvement in purity, which may be useful in enzyme replacement therapy (ERT) for the treatment of mucopolysaccharidosis type III.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
The present invention provides a cycloalkane-based lipid compound of chemical formula 1, and a pharmaceutically acceptable salt thereof. The cycloalkane-based lipid compound is formed such that a carbonyl-based substituent is bonded to a central structure of a cycloalkane. The cycloalkane-based lipid compound according to the present invention is used as an ionizable lipid, which is one component of lipid nanoparticles for delivering nucleic acids.
C07C 237/24 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant l'atome de carbone d'au moins un des groupes carboxamide lié à un atome de carbone d'un cycle autre qu'un cycle aromatique à six chaînons du squelette carboné
C07C 219/12 - Composés contenant des groupes amino et hydroxy estérifiés liés au même squelette carboné ayant des groupes hydroxy estérifiés et des groupes amino liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé au moins un des groupes hydroxy étant estérifié par un acide carboxylique ayant le groupe carboxyle estérifiant lié à un atome de carbone d'un cycle autre qu'un cycle aromatique à six chaînons
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
The present invention relates to a novel ionizable lipid compound represented by formula (I) or a salt thereof, and lipid nanoparticles including the same. Lipid nanoparticles including a novel ionizable lipid compound according to the present invention have excellent nucleic acid encapsulation efficiency and high cell delivery efficiency of nucleic acids.
C07D 295/13 - Composés hétérocycliques contenant des cycles polyméthylène imine d'au moins cinq chaînons, des cycles aza-3 bicyclo [3.2.2] nonane, piperazine, morpholine ou thiomorpholine, ne comportant que des atomes d'hydrogène liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes d'azote du cycle substitués par des atomes d'azote liés par des liaisons simples ou doubles avec les atomes d'azote du cycle et les atomes d'azote substituants liés à la même chaîne carbonée, qui n'est pas interrompue par des cycles carbocycliques à une chaîne acyclique saturée
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
11.
NOVEL SALT OF DIMETHYL-2,3-DIHYDRO-1H-INDENE DERIVATIVE AND PROCESSES FOR PREPARING THE SAME
The present invention provides a novel salt of (S)-quinuclidin-3-yl ((R)-5-(3-chloro-4-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate, i.e., (1S)-(+)-10-camphorsulfonic acid salt thereof and a process for preparing the same. The (1S)-(+)-10-camphorsulfonic acid salt of (S)-quinuclidin-3-yl ((R)-5-(3-chloro-4-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate is obtained in a crystalline form and has high purity, high stability, high water-solubility, and low hygroscopicity.
The present invention provides an improved process for preparing a dimethyl-2,3-dihydro-1H-indene derivative or a pharmaceutically acceptable salt thereof. And, the present invention provides novel intermediates useful for the process. When a compound of Formula 1 or its stereoisomer is prepared via the novel intermediate(s) according to the present invention, it is possible to minimize the amount of heavy metal (Pd) remaining in the final product, i.e., the compound of Formula 1 or its stereoisomer. In addition, the process of the present invention makes it possible to prepare a stereoisomer of the compound of Formula 1 or a pharmaceutically acceptable salt thereof in high optical purity.
C07D 453/02 - Composés hétérocycliques contenant des systèmes cycliques quinuclidine ou isoquinuclidine, p. ex. alcaloïdes de la quinine contenant des systèmes cycliques quinuclidine sans autre condensation
A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p. ex. quinuclidine
C07C 211/42 - Composés contenant des groupes amino liés à un squelette carboné ayant des groupes amino liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons d'un squelette carboné non saturé contenant des systèmes cycliques condensés avec des cycles aromatiques à six chaînons faisant partie des systèmes cycliques condensés
C07C 217/74 - Composés contenant des groupes amino et hydroxy éthérifiés liés au même squelette carboné ayant des groupes hydroxy éthérifiés liés à des atomes de carbone d'au moins un cycle aromatique à six chaînons et des groupes amino liés à des atomes de carbone acycliques ou à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons du même squelette carboné avec des cycles autres que des cycles aromatiques à six chaînons faisant partie du squelette carboné
C07C 209/68 - Préparation de composés contenant des groupes amino liés à un squelette carboné à partir d'amines, par des réactions n'impliquant pas de groupes amino, p. ex. réduction d'amines non saturées, aromatisation ou substitution du squelette carboné
C07C 211/38 - Composés contenant des groupes amino liés à un squelette carboné ayant des groupes amino liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons d'un squelette carboné saturé contenant des systèmes cycliques condensés
C07C 217/56 - Composés contenant des groupes amino et hydroxy éthérifiés liés au même squelette carboné ayant des groupes hydroxy éthérifiés liés à des atomes de carbone d'au moins un cycle aromatique à six chaînons et des groupes amino liés à des atomes de carbone acycliques ou à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons du même squelette carboné avec des groupes amino reliés au cycle aromatique à six chaînons, ou au système cyclique condensé contenant ce cycle, par l'intermédiaire de chaînes carbonées qui ne sont pas substituées de plus par des atomes d'oxygène liés par des liaisons simples
The present invention is related to a method for purifying heparan-N-sulfatase from a heparan-N-sulfatase-containing solution including at least one impurity, the method comprising performing multi-mode chromatography (MMC) to obtain an eluate; and performing caprylate precipitation to obtain a supernatant. The method according to the present invention is capable of very efficiently removing HCP (host cell proteins) and of greatly improving the purity and stability of purified heparan-N-sulfatase.
The present invention relates to a method for purification of hemopexin and haptoglobin and provides a method in which a solution containing hemopexin and haptoglobin is titrated to a range of specific pH values without a step of precipitating haptoglobin by salt addition, followed by separating and purifying hemopexin and haptoglobin individually.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
B01D 15/36 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction ionique, p. ex. échange d'ions, paire d'ions, suppression d'ions ou exclusion d'ions
15.
LIPID NANOPARTICLES USING CATIONIC CHOLESTEROL FOR LOCAL DELIVERY FOR NUCLEIC ACID DELIVERY
The present invention is directed to lipid nanoparticles using cationic cholesterol for topical delivery for nucleic acid delivery, and when administered locally, side effects caused by systemic drug delivery can be minimized and protein expression can be confined to the site of administration. In addition, the duration of protein expression at the site of administration can be increased, and thus the lipid nanoparticles can be useful in the technical field related to nucleic acid therapeutics.
A61K 47/28 - Stéroïdes, p. ex. cholestérol, acides biliaires ou acide glycyrrhétinique
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-encapsulation, p. ex. utilisant des vésicules liposomiques
16.
Coronavirus Spike Protein-Specific Antibody and Use Thereof
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
17.
ADAMTS13 VARIANT HAVING INCREASED ESCAPING RATE OR ACTIVITY AGAINST AUTOANTIBODY
An ADAMTS13 mutant protein having an improved escaping rate against an autoantibody and a composition that is suitable for preventing or treating thrombotic diseases are disclosed. By efficiently avoiding autoantibodies known to have high binding affinity to the main domain of ADAMTS13, the ADAMTS13 variant protein of the present invention can be used as an effective therapeutic composition for various thrombotic diseases, such as TTP (thrombotic thrombocytopenic purpura), in which the presence of such autoantibodies is the main etiology, and can stably maintain the biological activity thereof when administered into a body. In addition, a newly identified site within ADAMTS13, which is recognized by an autoantibody can be used in screening novel ADAMTS13 variants having an improved autoantibody escaping rate by applying a combination of various mutations within the corresponding site.
The present invention relates to a pharmaceutical formulation composition for a plasma protein, particularly an ADAMTS-13 protein, and a composition for the prevention or treatment of thrombotic diseases, comprising same. The present invention significantly improves the stability of plasma protein, which has a high risk of denaturation and contamination from the moment of separation and purification from blood, resulting in deterioration in pharmacological activity and quality during long-term storage, and in particular, maintains colloidal stability, refrigeration stability, purity and an aggregation blocking rate at high levels and maintains good cake properties after freeze-drying for a long period of time, and thus can be effectively used in maintaining and storing the ADAMTS-13 protein, which is an important therapeutic resource used for various thrombotic diseases, for a long period of time without loss of the therapeutically effective amount thereof.
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
The present invention relates to a pharmaceutical formulation composition for plasma proteins, specifically ADAMTS-13 protein, and a composition for preventing or treating thrombotic diseases comprising same. The present invention significantly improves the stability of plasma proteins, which, from the moment of being isolated and purified from blood, have a high risk of denaturation and contamination, thereby resulting in a decrease in pharmacological activity and quality during long-term storage, and, in particular, maintains colloidal stability, refrigeration stability, purity, and aggregation inhabitation at a high level, as well as maintaining good cake properties after lyophilization for a long period of time, such that the present invention can be effectively used for maintaining and storing ADAMTS-13 protein, which is an important therapeutic resource used for various thrombotic diseases, for a long period of time without loss of a therapeutically effective amount.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
The present invention relates to a lyophilized formulation including a fusion protein of α-galactosidase A and a preparation method thereof, wherein the lyophilized formulation not only has storage stability by including a composition providing structural stability to a fusion protein of α-galactosidase A, but also has excellent stability although the fusion protein is contained at a high concentration.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p. ex. cellulases, lactases
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
21.
LIQUID FORMULATION COMPRISING A FUSION PROTEIN INCLUDING α-GALACTOSIDASE A
The present invention relates to a liquid formulation including a fusion protein of α-galactosidase A and a preparation method thereof, wherein the liquid formulation not only has storage stability by including a composition providing structural stability to a fusion protein of α-galactosidase A, but also has excellent stability although the fusion protein is contained at a high concentration.
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p. ex. cellulases, lactases
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
22.
METHOD FOR PRODUCTION OF VARICELLA ZOSTER VIRUS SURFACE PROTEIN ANTIGEN
A method for production of a Varicella Zoster Virus surface protein antigen is disclosed. The method for production of a Varicella Zoster Virus surface protein antigen is an effective production method capable of obtaining the Varicella Zoster Virus surface protein antigen in high yield and high purity. Therefore, the method is useful for production of the Varicella Zoster Virus surface protein antigen for use as a vaccine composition for preventing or treating varicella or herpes zoster.
Disclosed is a method of purifying factor XIII comprising (a) first salt precipitation, (b) heat treatment, and (c) second salt precipitation, in which factor XIII can be purified at high yield from a plasma sample or the like through a simple process, and factor XIII can be purified with high purity. In addition, since this method can be applied to large-scale industrial production, it is an economical and efficient purification method, and can be useful in the field of prevention and treatment of diseases associated with factor XIII deficiency.
Mogam Institute For Biomedical Research (République de Corée)
Inventeur(s)
Kim, Ki Su
Jeong, Jun Hong
Yoon, Ae Rin
Song, Eun Jung
Choi, Hye Ji
Lim, Ok Jae
Lee, Yun Jung
Lim, Hyung Kwon
Won, Jong Wha
Abrégé
An anti-CD3 antibody and a pharmaceutical composition, and their uses are disclosed. The anti-CD3 antibody are useful for treating or preventing cancer. The antibody has high affinity and specificity for CD3 and thus can be effectively used in cancer prevention or treatment.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
25.
5'-UTR WITH IMPROVED TRANSLATION EFFICIENCY, A SYNTHETIC NUCLEIC ACID MOLECULE INCLUDING THE SAME, AND A VACCINE OR THERAPEUTIC COMPOSITION INCLUDING THE SAME
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
GREEN CROSS CORPORATION (République de Corée)
Inventeur(s)
Shin, Min-Kyung
Ha, Hongseok
Park, Joori
Lee, Sena
Kim, Yoon Ki
Jung, Jaesung
Lee, Yoon Suk
Kwon, Hyokyoung
Kim, Tae-Hee
Yun, Yeomin
Abrégé
Disclosed are a synthetic nucleic acid molecule including 5'-UTR with improved translation efficiency and a vaccine/therapeutic composition including the same, and more particularly, a 5'-UTR polynucleotide that is imparted with improved translation efficiency based on the specific motif thereof, a synthetic nucleic acid molecule including the same and a vaccine/therapeutic composition including the synthetic nucleic acid molecule. The 5'-UTR polynucleotide effectively induces expression of target proteins due to improved translation efficiency thereof and thus is useful for various RNA-based applications, for example, vaccines, in vivo/ex vivo gene therapy, etc.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
5'-UTR WITH IMPROVED TRANSLATION EFFICIENCY, A SYNTHETIC NUCLEIC ACID MOLECULE INCLUDING THE SAME, AND A VACCINE OR THERAPEUTIC COMPOSITION INCLUDING THE SAME
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
GREEN CROSS CORPORATION (République de Corée)
Inventeur(s)
Shin, Min-Kyung
Ha, Hongseok
Park, Joori
Lee, Sena
Kim, Yoon Ki
Jung, Jaesung
Lee, Yoon Suk
Kwon, Hyokyoung
Kim, Tae-Hee
Yun, Yeomin
Abrégé
Disclosed are a synthetic nucleic acid molecule including 5'-UTR with improved translation efficiency and a vaccine/therapeutic composition including the same, and more particularly, a 5'-UTR polynucleotide that is imparted with improved translation efficiency based on the specific motif thereof, a synthetic nucleic acid molecule including the same and a vaccine/therapeutic composition including the synthetic nucleic acid molecule. The 5'-UTR polynucleotide effectively induces expression of target proteins due to improved translation efficiency thereof and thus is useful for various RNA-based applications, for example, vaccines, in vivo/ex vivo gene therapy, etc.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
27.
NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST GLUCOSYLCERAMIDE SYNTHASE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESSES FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
Provided are a compound having a chromane, isochromane, thiochromane, or tetrahydroquinoline moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof, wherein the compound having a chromane, isochromane, thiochromane, or tetrahydroquinoline moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
NOVEL DERIVATIVES HAVING 2,3-DIHYDRO-1H-INDENE OR 2,3-DIHYDROBENZOFURAN MOIETY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
Provided are a compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same and a use thereof, where the compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
NOVEL DERIVATIVES HAVING 1,2,3,4-TETRAHYDRONAPHTHALENE MOIETY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
Provided are a compound having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same and a use thereof, where the compound having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
C07D 453/02 - Composés hétérocycliques contenant des systèmes cycliques quinuclidine ou isoquinuclidine, p. ex. alcaloïdes de la quinine contenant des systèmes cycliques quinuclidine sans autre condensation
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
30.
NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST GLUCOSYLCERAMIDE SYNTHASE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESSES FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAM
The present invention provides a novel compound having an inhibitory activity against glucosylceramide synthase (GCS), i.e., compounds having a 2,3-dihydro-1H-indene, 1,2,3,4-tetrahydronaphthalene, or chromane moiety, or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof. The compound or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and exhibits the effects of alleviating symptoms in the central nervous system as well as in the peripheral nervous system, through excellent blood-brain barrier permeability. Therefore, the compound or pharmaceutically acceptable salt thereof can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
C07D 453/02 - Composés hétérocycliques contenant des systèmes cycliques quinuclidine ou isoquinuclidine, p. ex. alcaloïdes de la quinine contenant des systèmes cycliques quinuclidine sans autre condensation
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
Inventeur(s)
Oh, Mi-Young
Lee, Jae-Chul
Park, Hye Young
Yum, Hye In
Kim, Dong-Sik
Abrégé
A steric epitope of CEACAM1 is disclosed. An anti-CEACAM1 antibody or a fragment thereof, which specifically binds to CEACAM1 is disclosed. A steric epitope of CEACAM1 includes all amino acids in critical positions for specific binding to an anti-CEACAM1 antibody and maintains an appropriate three-dimensional structure, and thus can high affinity for an anti-CEACAM1 antibody. In addition, an antibody, or a fragment thereof, that specifically binds to a steric epitope can effectively suppress CEACAM1-CEACAM1 interaction and CEACAM1-CEACAM6 interaction.
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The present invention relates to a pharmaceutical composition for treating, or for use for treating hepatitis B comprising an HBV-specific antibody for use in combination with a vaccine composition, and more particularly a pharmaceutical composition for treating hepatitis B comprising an HBV-specific antibody having a specific amino acid sequence for use in treating hepatitis B in combination with an adenovirus-based therapeutic vaccine composition having a nucleotide sequence encoding a hepatitis B virus-specific antigen, and a method for treating hepatitis B using a combination of the pharmaceutical composition and the vaccine composition. According to the present invention, co-administration of the HBV vaccine therapeutic agent "TG1050" and the antibody "GC1102" capable of binding to the HBV surface antigen (HBsAg), which have different mechanisms of action, is very effective in preventing or treating hepatitis B caused by HBV infection, compared to single administration of TG1050 or GC1102.
A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
33.
FUSION PROTEIN COMPRISING ANTI-MESOTHELIN ANTIBODY, ANTI-CD3 ANTIBODY OR ANTI-EGFR ANTIBODY, BISPECIFIC OR TRISPECIFIC ANTIBODY COMPRISING SAME, AND USES THEREOF
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
Inventeur(s)
Lim, Yangmi
Lee, Shinai
Won, Jonghwa
Park, Yong-Yea
Yoon, Aerin
Lee, Sua
Lim, Okjae
Lim, Sojung
Kim, Munkyung
Abrégé
A fusion protein including a fragment of an anti-mesothelin antibody, an anti-CD3 antibody or an anti-EGFR antibody; a bispecific antibody that is specific to mesothelin and CD3; a trispecific antibody that is specific to mesothelin, CD3 and EGFR are provided. The fusion protein is effective in treating cancer. The bispecific or trispecific antibody can be prepared in a high yield and with high purity, and has excellent tumor killing and growth inhibitory effects, and thus can be effectively used in cancer treatment.
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The present invention relates to a self-administration assistance device and, more specifically, to a self-administration assistance device which comprises: a main body part comprising an insertion space to which a syringe module can be mounted, and a hollow space in communication with the insertion space; a cover part arranged on the exterior of the main body part and coupled to the main body part so as to be opened and closed; and a separation part which is mounted to the lower end of the main body part, comprises a needle hole in communication with the hollow space, and can slide vertically, wherein the syringe module comprises a needle and a needle cap surrounding the needle, the needle cap penetrating the needle hole when the syringe module is arranged in the insertion space, and being separated from the syringe module when the separation part moves downward, and, thereby, the fear of a syringe needle and a self-administration failure by a user, who is a non-medical professional, can be relieved, and the efficiency of self-administration can be improved.
A61M 5/32 - AiguillesParties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchonAccessoires pour introduire l'aiguille dans le corps ou l'y maintenirDispositifs pour la protection des aiguilles
A61M 5/46 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras avec des moyens pour commander la profondeur de pénétration
A61M 5/42 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras avec des moyens pour insensibiliser la peau, pour soulever la peau en vue de faciliter la piqûre ou pour localiser le point du corps où la piqûre doit être effectuée
35.
ADAMTS13 VARIANT HAVING INCREASED ESCAPING RATE OR ACTIVITY AGAINST AUTOANTIBODY
The present invention relates to an ADAMTS13 mutant protein having an improved escaping rate against an autoantibody and a composition for preventing or treating thrombotic diseases using same. By efficiently avoiding representative autoantibodies known to have high binding affinity to the main domain of ADAMTS13, the ADAMTS13 variant protein of the present invention can be used as an effective therapeutic composition for various thrombotic diseases, such as TTP (thrombotic thrombocytopenic purpura), etc., in which the presence of such autoantibodies is the main etiology, and can stably maintain the biological activity thereof when administered into a body. In addition, as a new site recognized by an autoantibody is identified within ADAMTS13, the present invention can be used usefully in screening novel ADAMTS13 variants having an improved autoantibody escaping rate by applying a combination of various mutations within the corresponding site.
C12N 9/64 - Protéinases provenant de tissu animal, p. ex. rennine
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
The present invention relates to an ADAMTS13 mutant protein having an improved escaping rate against an autoantibody and a composition for preventing or treating thrombotic diseases using same. By efficiently avoiding representative autoantibodies known to have high binding affinity to the main domain of ADAMTS13, the ADAMTS13 variant protein of the present invention can be used as an effective therapeutic composition for various thrombotic diseases, such as TTP (thrombotic thrombocytopenic purpura), etc., in which the presence of such autoantibodies is the main etiology, and can stably maintain the biological activity thereof when administered into a body. In addition, as a new site recognized by an autoantibody is identified within ADAMTS13, the present invention can be used usefully in screening novel ADAMTS13 variants having an improved autoantibody escaping rate by applying a combination of various mutations within the corresponding site.
C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
G01N 33/573 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour enzymes ou isoenzymes
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
Inventeur(s)
Park, Hye-Young
Song, Eun Jung
Lee, Eun Hee
Yum, Hye In
Nam, Hye Mi
Kim, Mun Kyung
Lee, Jee Won
Sheen, Joong Hyuk
Hur, Min Kyu
Lim, So Jung
Lim, Ok Jae
Lim, Yang Mi
Won, Jong Hwa
Abrégé
The present invention relates to: an antibody to T cell Immunoreceptor with Ig and Tyrosine-Based Inhibitory Motif Domains (TIGIT), or an antigen-binding fragment thereof; a nucleic acid encoding same; a vector carrying the nucleic acid; a cell transformed with the vector; a method for producing the antibody or the antigen-binding fragment thereof; and a composition and a composition for combined administration, which comprise same and are for preventing or treating cancer.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A bispecific anti-GPNMB/anti-CD3 antibody specifically binds to CD3 (cluster of differentiation 3) and GPNMB (glycoprotein non-metastatic melanoma protein B) and uses thereof are disclosed. The bispecific antibody shows high affinity and specificity to CD3 and GPNMB and thus can induce death of cancer cells expressing GPNMB and inhibit proliferation thereof. Therefore, the bispecific antibody can be used as an effective therapeutic agent for cancers expressing GPNMB.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
40.
CONFORMATIONAL EPITOPE OF HEPATITIS B SURFACE ANTIGEN AND ANTIBODY BINDING SPECIFICALLY THERETO
A specific conformational epitope of a hepatitis B surface antigen and a hepatitis B neutralizing antibody binding thereto are disclosed. The epitope has a specific conformational structure. In addition, the conformational epitope does not contain the ‘a’ determinant that may generate an escape mutation upon administration of conventional vaccines or HBIg. Thus, an antibody capable of binding to the epitope is highly unlikely to allow the emergence of a vaccine escape mutation, which is caused by conventional vaccines, and as such, can retain a sustained effect. Therefore, such an antibody or a vaccine composition can find effective applications in the prevention and treatment of HBV, having great economic value.
The present disclosure relates to a pharmaceutical highly efficient anti-TFPI antibody composition including an anti-TFPI antibody for treating hemophilia, in which the content of HCP in a drug substance is less than 10.0 ng/mg, and the content of LPA in the drug substance or the drug product is less than 1.0 ng/mg. According to the present disclosure, a highly efficient anti-TFPI antibody composition having very low contents of HCP and LPA may be provided by providing a separation/purification process capable of minimizing anti-TFPI antibody polymer generation, and may be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease.
The present invention relates to a method for production of a varicella zoster virus surface protein antigen. The method for production of a varicella zoster virus surface protein antigen according to the present invention is an effective production method by which a varicella zoster surface protein antigen can be obtained at high yield and purity. Therefore, the method is advantageous for producing a surface protein antigen of varicella zoster virus for use as a vaccine composition for prevention or treatment of chicken pox or herpes zoster.
Disclosed is a method for removing factor XI (FXI) during plasma protein purification, more specifically a method for removing FXI including dialyzing and concentrating a plasma protein fraction II paste containing FXI and a plasma protein, and then removing the FXI using a ceramic-based cation exchange resin. The method for removing factor XI (FXI) can improve removal efficiency of impurities and thrombogenic substances, thereby producing stable plasma proteins with improved quality.
B01D 15/36 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction ionique, p. ex. échange d'ions, paire d'ions, suppression d'ions ou exclusion d'ions
C07K 1/34 - ExtractionSéparationPurification par filtration, ultrafiltration ou osmose inverse
C07K 1/36 - ExtractionSéparationPurification par une combinaison de plusieurs procédés de types différents
C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
B01D 15/12 - Adsorption sélective, p. ex. chromatographie caractérisée par des caractéristiques de structure ou de fonctionnement relatives à la préparation de l'alimentation
B01D 15/20 - Adsorption sélective, p. ex. chromatographie caractérisée par des caractéristiques de structure ou de fonctionnement relatives au conditionnement de la matière adsorbante ou absorbante
B01D 15/18 - Adsorption sélective, p. ex. chromatographie caractérisée par des caractéristiques de structure ou de fonctionnement relatives aux différents types d'écoulement
G01N 30/14 - Préparation par élimination de certains composants
44.
METHOD AND COMPOSITION FOR TREATING HUNTER SYNDROME THROUGH CEREBRAL LATERAL VENTRICLE ADMINISTRATION
A pharmaceutical composition including an iduronate-2-sulfatase beta (IDS-β) may be administered into the cerebral lateral ventricle once every four weeks to treat Hunter syndrome in a subject. Compared to a single administration of the same dose of an active substance, due to repeated administrations over a long period of time, the administration exhibits superior effects in treating Hunter syndrome, and further has the following effects which cannot be anticipated from the result of a single administration: treating or restoring a damaged brain structure; and substantially treating or improving brain functions, particularly, improving memory and learning.
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
45.
NOVEL DERIVATIVES HAVING 2,3-DIHYDRO-1H-INDENE OR 2,3-DIHYDROBENZOFURAN MOIETY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
The present invention provides a novel compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof. The compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p. ex. quinuclidine
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
46.
NOVEL DERIVATIVES HAVING 2,3-DIHYDRO-1H-INDENE OR 2,3-DIHYDROBENZOFURAN MOIETY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
The present invention provides a novel compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof. The compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p. ex. quinuclidine
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
47.
NOVEL DERIVATIVES HAVING 1,2,3,4-TETRAHYDRONAPHTHALENE MOIETY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
The present invention provides a novel compound having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof. The compound having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p. ex. quinuclidine
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
48.
NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST GLUCOSYLCERAMIDE SYNTHASE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESSES FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
The present invention provides a novel compound having a chromane, isochromane, thiochromane, or tetrahydroquinoline moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof. The compound having a chromane, isochromane, thiochromane, or tetrahydroquinoline moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p. ex. quinuclidine
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
Inventeur(s)
Oh, Mi-Young
Lee, Jae-Chul
Park, Hye Young
Yum, Hye In
Kim, Dong-Sik
Abrégé
The present invention relates to a steric epitope of CEACAM1, and an anti-CEACAM1 antibody, or a fragment thereof, that specifically binds to same. A steric epitope of CEACAM1, of the present invention, comprises all amino acids in critical positions for specific binding to an anti-CEACAM1 antibody and maintains an appropriate three-dimensional structure, and thus can high affinity for an anti-CEACAM1 antibody. In addition, an antibody, or a fragment thereof, that specifically binds to a steric epitope, according to the present invention, can effectively suppress CEACAM1-CEACAM1 interaction and CEACAM1-CEACAM6 interaction.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
Inventeur(s)
Oh, Mi-Young
Lee, Jae-Chul
Park, Hye Young
Yum, Hye In
Kim, Dong-Sik
Abrégé
The present invention relates to a steric epitope of CEACAM1, and an anti-CEACAM1 antibody, or a fragment thereof, that specifically binds to same. A steric epitope of CEACAM1, of the present invention, comprises all amino acids in critical positions for specific binding to an anti-CEACAM1 antibody and maintains an appropriate three-dimensional structure, and thus can high affinity for an anti-CEACAM1 antibody. In addition, an antibody, or a fragment thereof, that specifically binds to a steric epitope, according to the present invention, can effectively suppress CEACAM1-CEACAM1 interaction and CEACAM1-CEACAM6 interaction.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
Inventeur(s)
Park, Hye-Young
Song, Eun Jung
Lee, Eun Hee
Yum, Hye In
Nam, Hye Mi
Kim, Mun Kyung
Lee, Jee Won
Sheen, Joong Hyuk
Hur, Min Kyu
Lim, So Jung
Lim, Ok Jae
Lim, Yang Mi
Won, Jong Hwa
Abrégé
The present invention relates to: an antibody to T cell Immunoreceptor with Ig and Tyrosine-Based Inhibitory Motif Domains (TIGIT), or an antigen-binding fragment thereof; a nucleic acid encoding same; a vector carrying the nucleic acid; a cell transformed with the vector; a method for producing the antibody or the antigen-binding fragment thereof; and a composition and a composition for combined administration, which comprise same and are for preventing or treating cancer.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
Inventeur(s)
Park, Hye-Young
Song, Eun Jung
Lee, Eun Hee
Yum, Hye In
Nam, Hye Mi
Kim, Mun Kyung
Lee, Jee Won
Sheen, Joong Hyuk
Hur, Min Kyu
Lim, So Jung
Lim, Ok Jae
Lim, Yang Mi
Won, Jong Hwa
Abrégé
The present invention relates to: an antibody to T cell Immunoreceptor with Ig and Tyrosine-Based Inhibitory Motif Domains (TIGIT), or an antigen-binding fragment thereof; a nucleic acid encoding same; a vector carrying the nucleic acid; a cell transformed with the vector; a method for producing the antibody or the antigen-binding fragment thereof; and a composition and a composition for combined administration, which comprise same and are for preventing or treating cancer.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A method for purification of a sulfatase using metal chelating chromatography without using tags such as His-tag, etc. is disclosed. An embodiment provides a method for purifying a sulfatase including the steps of: (a) providing a sulfatase-containing solution comprising one or a plurality of impurities; (b) performing a first chromatographic separation of the sulfatase-containing solution using a metal affinity chromatography resin; (c) performing a second chromatographic separation using a cation exchange chromatography resin; and (d) performing a final chromatographic separation using an anion exchange chromatography resin, wherein the impurities are removed thereby.
The present invention relates to an improved method of purifying an immunoglobulin, and more particularly to a method of purifying an immunoglobulin which is capable of sufficiently removing impurities from an immunoglobulin-containing plasma protein sample through a simple process, comprising a single anion-exchange chromatography and a single cation-exchange chromatography.
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
Inventeur(s)
Park, Jae Chan
Song, Eun Jung
Lim, So Jung
Lee, Jae-Chul
Kwon, Hae Naem
Lee, Su A
Lim, Ok Jae
Kim, Mun Kyung
Cho, Hyun Jung
Kim, Gil-Jung
Lee, Jee Won
Kim, Sung Keun
Won, Jong Wha
Jang, Shin A
Abrégé
The present invention relates to a bispecific anti-GPNMB/anti-CD3 antibody specifically binding to CD3 and GPNMB, and the use thereof. Particularly, the bispecific antibody shows high affinity and specificity to CD3 and GPNMB and thus can induce death of cancer cells expressing GPNMB and inhibit proliferation thereof. Therefore, the bispecific antibody can be used as an effective therapeutic agent for cancers expressing GPNMB.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
56.
BISPECIFIC ANTIBODY SPECIFICALLY BINDING TO GPNMB AND CD3, AND USE THEREOF
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
Inventeur(s)
Park, Jae Chan
Song, Eun Jung
Lim, So Jung
Lee, Jae-Chul
Kwon, Hae Naem
Lee, Su A
Lim, Ok Jae
Kim, Mun Kyung
Cho, Hyun Jung
Kim, Gil-Jung
Lee, Jee Won
Kim, Sung Keun
Won, Jong Wha
Jang, Shin A
Abrégé
The present invention relates to a bispecific anti-GPNMB/anti-CD3 antibody specifically binding to CD3 and GPNMB, and the use thereof. Particularly, the bispecific antibody shows high affinity and specificity to CD3 and GPNMB and thus can induce death of cancer cells expressing GPNMB and inhibit proliferation thereof. Therefore, the bispecific antibody can be used as an effective therapeutic agent for cancers expressing GPNMB.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
Inventeur(s)
Kim, Ki Su
Jeong, Jun Hong
Yoon, Ae Rin
Song, Eun Jung
Choi, Hye Ji
Lim, Ok Jae
Lee, Yun Jung
Lim, Hyung Kwon
Won, Jong Wha
Abrégé
The present invention relates to an anti-CD3 antibody and a pharmaceutical composition for cancer treatment comprising same. The antibody according to the present invention has high affinity and specificity for CD3 and thus can be effectively used in cancer prevention or treatment.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
58.
FUSION PROTEIN COMPRISING ANTI-MESOTHELIN ANTIBODY, ANTI-CD3 ANTIBODY OR ANTI-EGFR ANTIBODY, BISPECIFIC OR TRISPECIFIC ANTIBODY COMPRISING SAME, AND USES THEREOF
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
Inventeur(s)
Lim, Yangmi
Lee, Shinai
Won, Jonghwa
Park, Yong-Yea
Yoon, Aerin
Lee, Sua
Lim, Okjae
Lim, Sojung
Kim, Munkyung
Abrégé
The present invention relates to: a fusion protein comprising a fragment of an anti-mesothelin antibody, an anti-CD3 antibody or an anti-EGFR antibody; a bispecific antibody that is specific to mesothelin and CD3; a trispecific antibody that is specific to mesothelin, CD3 and EGFR; and uses thereof. The bispecific or trispecific antibody according to the present invention can be prepared in a high yield and with high purity, and has excellent tumor killing and growth inhibitory effects, and thus can be effectively used in cancer treatment.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
59.
FUSION PROTEIN COMPRISING ANTI-MESOTHELIN ANTIBODY, ANTI-CD3 ANTIBODY OR ANTI-EGFR ANTIBODY, BISPECIFIC OR TRISPECIFIC ANTIBODY COMPRISING SAME, AND USES THEREOF
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
Inventeur(s)
Lim, Yangmi
Lee, Shinai
Won, Jonghwa
Park, Yong-Yea
Yoon, Aerin
Lee, Sua
Lim, Okjae
Lim, Sojung
Kim, Munkyung
Abrégé
The present invention relates to: a fusion protein comprising a fragment of an anti-mesothelin antibody, an anti-CD3 antibody or an anti-EGFR antibody; a bispecific antibody that is specific to mesothelin and CD3; a trispecific antibody that is specific to mesothelin, CD3 and EGFR; and uses thereof. The bispecific or trispecific antibody according to the present invention can be prepared in a high yield and with high purity, and has excellent tumor killing and growth inhibitory effects, and thus can be effectively used in cancer treatment.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
Provided according to an embodiment of the present invention is an antibody that binds specifically to B-cell maturation antigen (BCMA) and comprises a heavy chain variable domain (VH domain) composed of a sequence having a homology of 80% or higher with any one of the amino acid sequences of SEQ ID NOS: 1 to 20, or a fragment thereof.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
61.
Methods and compositions for treating hunter syndrome
The present invention provides, among other things, compositions and methods for CNS delivery of Idursulfase-beta, a human recombinant iduronate-2-sulfatase protein, for effective treatment of Hunter Syndrome. The compositions and methods provided by the present invention effectively reduce symptoms not only in brain and spinal cord but also in peripheral tissues including heart, liver, spleen, lung, and kidney.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
62.
THREE-DIMENSIONAL EPITOPE OF HEPATITIS B SURFACE ANTIGEN AND ANTIBODY BINDING SPECIFICALLY THERETO
The present invention relates to a specific three-dimensional epitope of a hepatitis B surface antigen and a hepatitis B neutralizing antibody binding thereto. The epitope provided by the present invention has a specific three-dimensional structure. In addition, the three-dimensional epitope of the present application does not contain the 'a' determinant that may generate an escape mutation upon administration of conventional vaccines or HBIg. Thus, an antibody capable of binding to the three-dimensional epitope of the present application is highly unlikely to allow the emergence of a vaccine escape mutation, which is caused by conventional vaccines, and as such, can retain a sustained effect. Therefore, such an antibody or a vaccine composition can find effective applications in the prevention and treatment of HBV, having great economic value.
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
GREEN CROSS CORPORATION (République de Corée)
Inventeur(s)
Eun, So-Young
Oh, Miyoung
Park, Hye-Young
Lee, Mijung
Yoon, Aerin
Yum, Hye In
Nam, Hyemi
Lee, Eunhee
Won, Jongwha
Abrégé
The present invention provides anti-CEACAM1 antibodies with improved binding abilities specific to CEACAM1, and a use thereof. Anti-CEACAM1 antibodies according to the present invention exhibit superior binding abilities specific to CEACAM1, and also activate the anti-cancer immune functions of cytotoxic T cells and natural killer cells, and thus, each one of them can be effectively used as an anti-cancer agent and a composition for treating cancer.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The present disclosure relates to a pharmaceutical highly efficient anti-TFPI antibody composition including an anti-TFPI antibody for treating hemophilia, in which the content of HCP in a drug substance is less than 10.0 ng/mg, and the content of LPA in the drug substance or the drug product is less than 1.0 ng/mg. According to the present disclosure, a highly efficient anti-TFPI antibody composition having very low contents of HCP and LPA may be provided by providing a separation/purification process capable of minimizing anti-TFPI antibody polymer generation, and may be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease.
The present disclosure relates to a pharmaceutical highly efficient anti-TFPI antibody composition including an anti-TFPI antibody for treating hemophilia, in which the content of HCP in a drug substance is less than 10.0 ng/mg, and the content of LPA in the drug substance or the drug product is less than 1.0 ng/mg. According to the present disclosure, a highly efficient anti-TFPI antibody composition having very low contents of HCP and LPA may be provided by providing a separation/purification process capable of minimizing anti-TFPI antibody polymer generation, and may be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease.
DAEWOONG PHARMACEUTICAL CO., LTD. (République de Corée)
GREEN CROSS CORPORATION (République de Corée)
Inventeur(s)
Yoon, Hee-Kyoon
Park, Se-Hwan
Yoon, Ji-Sung
Choi, Soongyu
Seo, Hee Jeong
Park, Eun-Jung
Kong, Younggyu
Song, Kwang-Seop
Kim, Min Ju
Park, So Ok
Abrégé
The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.
C07D 409/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 407/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
In one aspect, the present invention relates to a pharmaceutical composition comprising iduronate-2-sulfatase beta (IDS-β), which may be administered into the cerebral lateral ventricle once every four weeks to treat Hunter syndrome in a subject. Compared to a single administration of the same dose of an active substance, the present invention, due to repeated administrations over a long period of time, exhibits superior effects in treating Hunter syndrome, and further has the following effects which cannot be anticipated from the result of a single administration: treating or restoring a damaged brain structure; and substantially treating or improving brain functions, particularly, improving memory and learning.
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
70.
BORDETELLA PERTUSSIS-DERIVED PROTEIN-OBTAINING METHOD INCLUDING AFFINITY CHROMATOGRAPHY PROCESS
The present invention relates to a Bordetella pertussis-derived protein-obtaining method including an affinity chromatography process. The present invention increases the production yield of PT and FHA proteins by isolating PT and FHA proteins of Bordetella pertussis through a purification process using a blue affinity column. In addition, when used, the filtration process can remarkably increase the output of the target proteins, compared to an isolation method using a size exclusion chromatography (SEC) process. Furthermore, the method using the blue affinity column for isolation of PT and FHA proteins decreased resin expense, process time, buffer consumption, and production cost and significantly increased the productivity of PT and FHA proteins.
C07K 14/235 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Bordetella (G)
C07K 1/16 - ExtractionSéparationPurification par chromatographie
C07K 1/20 - Chromatographie de partage, de phase inverse ou d'interaction hydrophobe
C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
B01D 15/38 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction spécifique non couverte par un ou plusieurs des groupes , p. ex. chromatographie d'affinité, chromatographie d'échange par ligand ou chromatographie chirale
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical agents affecting metabolism for liver
disease; biological preparations for liver disease; blood
solvent for treating liver disease; nutritional supplements,
namely, tonics and alteratives for medical purposes;
hepatitis vaccine; preparations for treatment of hepatitis;
drugs for medical purposes; pharmaceutical products for the
treatment of viral diseases; vaccines; chemical preparations
for medicinal purposes; pharmaceuticals and pharmaceutical
preparations for the treatment of infectious diseases, viral
disease; pharmaceuticals.
DAEWOONG PHARMACEUTICAL CO., LTD. (République de Corée)
GREEN CROSS CORPORATION (République de Corée)
Inventeur(s)
Yoon, Hee-Kyoon
Park, Se-Hwan
Yoon, Ji-Sung
Choi, Soongyu
Seo, Hee Jeong
Park, Eun-Jung
Kong, Younggyu
Song, Kwang-Seop
Kim, Min Ju
Park, So Ok
Abrégé
The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.
C07D 409/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 407/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
The present invention relates to a method for purification of immunoglobulins and, more particularly, to a method for purification of immunoglobulins, the method comprising anion exchange chromatography and cation exchange chromatography for plasma samples including immunoglobulins.
The present invention relates to a method for purification of immunoglobulins and, more particularly, to a method for purification of immunoglobulins, the method comprising anion exchange chromatography and cation exchange chromatography for plasma samples including immunoglobulins.
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
GREEN CROSS CORPORATION (République de Corée)
Inventeur(s)
Kim, Ki Su
Jeong, Jun Hong
Yoon, Ae Rin
Song, Eun Jung
Choi, Hye Ji
Lim, Ok Jae
Lee, Yun Jung
Lim, Hyung Kwon
Won, Jong Wha
Abrégé
The present invention relates to an anti-CD3 antibody and a pharmaceutical composition for cancer treatment comprising same. The antibody according to the present invention has high affinity and specificity for CD3 and thus can be effectively used in cancer prevention or treatment.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
76.
ANTI-CD3 ANTIBODY AND PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT COMPRISING SAME
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
Inventeur(s)
Kim, Ki Su
Jeong, Jun Hong
Yoon, Ae Rin
Song, Eun Jung
Choi, Hye Ji
Lim, Ok Jae
Lee, Yun Jung
Lim, Hyung Kwon
Won, Jong Wha
Abrégé
The present invention relates to an anti-CD3 antibody and a pharmaceutical composition for cancer treatment comprising same. The antibody according to the present invention has high affinity and specificity for CD3 and thus can be effectively used in cancer prevention or treatment.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
77.
ANTI-MSLN ANTIBODY AND PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT COMPRISING SAME
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
Inventeur(s)
Kim, Ki Su
Jeong, Jun Hong
Kim, Dong Sik
Lim, Yang Mi
Park, Yong Yea
Lim, Hyung Kwon
Won, Jong Wha
Abrégé
The present invention relates to an anti-MSLN antibody and a pharmaceutical composition for cancer treatment comprising same. The anti-MSLN antibody according to the present invention has high affinity and specificity for MSLN and thus can be effectively used in cancer prevention or treatment.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
78.
Pharmaceutical composition for inhibiting metastasis of cancer, comprising, as active ingredient, antibody that specifically binds to epidermal growth factor receptor
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
Inventeur(s)
Won, Jong-Hwa
Lim, Yangmi
Hur, Min-Kyu
Abrégé
The present invention provides a pharmaceutical composition for inhibiting the metastasis of cancer, comprising, as an active ingredient, an antibody that specifically binds to an epidermal growth factor receptor, and a method for inhibiting the metastasis of cancer using the composition. The composition or the method is effective in inhibiting the invasion of various gastric cancer cell lines induced by EGFR ligands. Therefore, the pharmaceutical composition can be usefully used for inhibiting the metastasis of cancer.
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
79.
ANTI-MSLN ANTIBODY AND PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT COMPRISING SAME
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
Inventeur(s)
Kim, Ki Su
Jeong, Jun Hong
Kim, Dong Sik
Lim, Yang Mi
Park, Yong Yea
Lim, Hyung Kwon
Won, Jong Wha
Abrégé
The present invention relates to an anti-MSLN antibody and a pharmaceutical composition for cancer treatment comprising same. The anti-MSLN antibody according to the present invention has high affinity and specificity for MSLN and thus can be effectively used in cancer prevention or treatment.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
80.
ANTI-BCMA ANTIBODY HAVING HIGH AFFINITY FOR BCMA AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SAME
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
GREEN CROSS CORPORATION (République de Corée)
DANA FARBER CANCER INSTITUTE, INC. (USA)
Inventeur(s)
Choi, Hye-Ji
Park, Jae-Chan
Lim, Hyung-Kwon
Abrégé
Provided according to an embodiment of the present invention is an antibody that binds specifically to B-cell maturation antigen (BCMA) and comprises a heavy chain variable domain (VH domain) composed of a sequence having a homology of 80% or higher with any one of the amino acid sequences of SEQ ID NOS: 1 to 20, or a fragment thereof.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
81.
FACTOR VIII OR FACTOR IX GENE KNOCKOUT RABBIT, METHOD FOR PREPARING SAME AND USE THEREOF
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
Inventeur(s)
Kim, So Ra
Jung, Myung Eun
Kim, Min Jung
Jo, Seung Hyun
Hwang, Sung Ho
Kwak, Hee Chun
Lee, Su Min
Nam, Hyun Ja
Abrégé
The present invention relates to a factor VIII or factor IX gene knockout rabbit, a method for preparing the same and a use thereof and, more particularly, to a transgenic rabbit whose factor VIII or factor IX gene has been knocked out through the CRISPR/Cas9 system, a method for preparing the same and a use thereof. According to the present invention, in the transgenic rabbit, whose factor VIII and/or factor IX gene has been knocked out, the functions of factor VIII and/or factor IX, which are proteins that perform critical functions for the development of hemophilia, are inhibited, such that the transgenic rabbit is useful for the development of hemophilia treatments.
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
GREEN CROSS CORPORATION (République de Corée)
Inventeur(s)
Choi, Hye-Ji
Park, Jae-Chan
Lim, Hyung-Kwon
Abrégé
Provided according to an embodiment of the present invention is an antibody that binds specifically to B-cell maturation antigen (BCMA) and comprises a heavy chain variable domain (VH domain) composed of a sequence having a homology of 80% or higher with any one of the amino acid sequences of SEQ ID NOS: 1 to 20, or a fragment thereof.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The present invention provides a method for purification of a sulfatase using metal chelating chromatography without use of tags (such as His-tag, etc.). An embodiment provides a method for purifying a sulfatase comprising the steps of: (a) providing a sulfatase-containing solution comprising one or a plurality of impurities; (b) performing a first chromatographic separation of the sulfatase-containing solution using a metal affinity chromatography resin; (c) performing a second chromatographic separation using a cation exchange chromatography resin; and (d) performing a final chromatographic separation using an anion exchange chromatography resin, wherein the impurities are removed thereby.
C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
C07K 1/34 - ExtractionSéparationPurification par filtration, ultrafiltration ou osmose inverse
C07K 1/36 - ExtractionSéparationPurification par une combinaison de plusieurs procédés de types différents
B01D 15/36 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction ionique, p. ex. échange d'ions, paire d'ions, suppression d'ions ou exclusion d'ions
B01D 15/38 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction spécifique non couverte par un ou plusieurs des groupes , p. ex. chromatographie d'affinité, chromatographie d'échange par ligand ou chromatographie chirale
84.
BORDETELLA PERTUSSIS-DERIVED PROTEIN, COMPRISING FREEZING AND THAWING PROCESS
C07K 14/235 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Bordetella (G)
C07K 1/16 - ExtractionSéparationPurification par chromatographie
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
GREEN CROSS CORPORATION (République de Corée)
Inventeur(s)
Kim, Dong-Sik
Song, Eun Jung
Lee, Mijung
Lee, Eun-Hee
Oh, Miyoung
Park, Jae Chan
Kim, Kisu
Kim, Sujeong
Lim, Hyung-Kwon
Lee, Kyuhyun
Won, Jongwha
Choi, Soongyu
Park, Young Seoub
Abrégé
The present invention relates to an antibody specifically bound to mesothelin (MSLN), a nucleic acid encoding the antibody, a vector and a host cell including the nucleic acid, a method for producing the antibody, and a pharmaceutical composition for treating cancer or tumor including the antibody as an active ingredient. The antibody specifically bound to the mesothelin according to the present invention has high affinity and specificity to an antigen, such that it is possible to develop an antibody effectively usable for treatment or diagnosis of cancer or tumor diseases.
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
GREEN CROSS CORPORATION (République de Corée)
Inventeur(s)
Kim, Ki Su
Jeong, Jun Hong
Lim, Hyung Kwon
Ryu, Jae Hwan
Kwon, Hae Naem
Lim, Yang Mi
Park, Yong Yea
Lee, Eun Hee
Won, Jong Hwa
Lim, Ok Jae
Shin, Duck Hyang
Kim, Mun Kyung
Lee, Yun Jung
Lee, Jee Won
Nam, Hyo Jung
Abrégé
The present invention relates to a bispecific antibody binding to HER3 and CD3, the antibody comprising a first polypeptide of SEQ ID NO: 1, a second polypeptide of SEQ ID NO: 2, a third polypeptide selected from the group consisting of SEQ ID NOS: 3 and 5, and a fourth polypeptide selected from the group consisting of SEQ ID NOS: 4 and 6, and showing excellent effects of engaging immune cells specifically with HER3-positive cells and inducing the growth suppression and death of HER3-positive cells, without causing side effects attributed to non-specific cytotoxicity.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
87.
Hunter syndrome therapeutic agent and treatment method
A Hunter syndrome therapeutic agent contains a first composition to be intravenously injected and a second composition to be subcutaneously injected. The agent can reduce the number of visits to the hospital by patients with Hunter syndrome to twice a month or less. It maintains a medicinal effect equivalent to or greater than that of a conventional once-a-week IV injection, increases drug-taking compliance of patients in comparison to conventional therapeutic agents and treatment methods, and enables enhanced patient welfare and convenience.
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
GREEN CROSS CORPORATION (République de Corée)
Inventeur(s)
Eun, So-Young
Oh, Miyoung
Park, Hye-Young
Lee, Mijung
Yoon, Aerin
Yum, Hye In
Nam, Hyemi
Lee, Eunhee
Won, Jongwha
Abrégé
The present invention provides anti-CEACAM1 antibodies with improved binding abilities specific to CEACAM1, and a use thereof. Anti-CEACAM1 antibodies according to the present invention exhibit superior binding abilities specific to CEACAM1, and also activate the anti-cancer immune functions of cytotoxic T cells and natural killer cells, and thus, each one of them can be effectively used as an anti-cancer agent and a composition for treating cancer.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
GREEN CROSS CORPORATION (République de Corée)
Inventeur(s)
Eun, So-Young
Oh, Miyoung
Park, Hye-Young
Lee, Mijung
Yoon, Aerin
Yum, Hye In
Nam, Hyemi
Lee, Eunhee
Won, Jongwha
Abrégé
The present invention provides anti-CEACAM1 antibodies with improved binding abilities specific to CEACAM1, and a use thereof. Anti-CEACAM1 antibodies according to the present invention exhibit superior binding abilities specific to CEACAM1, and also activate the anti-cancer immune functions of cytotoxic T cells and natural killer cells, and thus, each one of them can be effectively used as an anti-cancer agent and a composition for treating cancer.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
90.
METHOD FOR REMOVING FXI WHEN PURIFYING PLASMA PROTEINS
The present invention relates to a method for removing factor XI (FXI) when purifying plasma proteins and, more particularly, to a method for removing FXI with a cation exchange resin made of a ceramic material after concentration with dialysis of a plasma protein fraction II paste containing FXI and plasma proteins. As the method for removing FXI according the present invention increases the removal efficiency of impurities and thrombogenic materials, plasma proteins that are stable and have improved quality can be produced.
The present invention relates to a method for removing factor XI (FXI) when purifying plasma proteins and, more particularly, to a method for removing FXI with a cation exchange resin made of a ceramic material after concentration with dialysis of a plasma protein fraction II paste containing FXI and plasma proteins. As the method for removing FXI according the present invention increases the removal efficiency of impurities and thrombogenic materials, plasma proteins that are stable and have improved quality can be produced.
A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter Syndrome.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
The present invention relates to an improved method for producing a diphenylmethane derivative useful as a sodium-dependent glucose cotransporter (SGLT) inhibitor. Performed in a convergent synthesis manner in which main groups are individually synthesized and then coupled, the method is simpler in synthesis pathway than linear synthesis manners disclosed in prior art documents, and can increase yield and reduce risk factors intrinsic in linear synthesis pathways.
C07D 407/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
A61K 31/35 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle
A61K 31/36 - Composés contenant des groupes méthylènedioxyphényle, p. ex. sésamine
The present invention provides a pharmaceutical formulation comprising an anti-epidermal growth factor receptor (EGFR) antibody. The pharmaceutical formulation has low turbidity, without showing aggregation or particle formation, even under accelerated conditions, and exhibits good stability. Therefore, the pharmaceutical formulation can be effectively used for the treatment of disorders such as cancer.
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
95.
RECOMBINANT SINGLE-CHAIN FVIII AND CHEMICAL CONJUGATE THEREOF
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
GREEN CROSS CORPORATION (République de Corée)
Inventeur(s)
Kang, Kwan-Yub
Lee, Seung-Hoon
Oh, Injae
Oh, Mee Sook
Ryu, Jae Hwan
Jo, Eui-Cheol
Lee, Ki-Nam
Yang, Sun-Ah
Abrégé
The present application provides a single-chain blood coagulation factor VIII including a B region which is partially deleted to contain at least four glycosylation sites, but not a heavy chain, a light-chain, and a region to be cleaved by proteases, or a single-chain blood coagulation factor VIII in which the A or B region has some residues pegylated. A single-chain blood coagulation factor VIII according to the present application not only retains intact therapeutic efficacy and can be easily produced on mass scale because of its single chain form, but also has an increased half-life in vivo through pegylation, thus enhancing convenience for patients as a therapeutic agent for hemophilia A and bringing about a reduction of medical expenses through reduction in production cost.
DAEWOONG PHARMACEUTICAL CO., LTD. (République de Corée)
GREEN CROSS CORPORATION (République de Corée)
Inventeur(s)
Choi, Soongyu
Kim, Min Ju
Kong, Younggyu
Park, Eun-Jung
Park, Se-Hwan
Park, So Ok
Seo, Hee Jeong
Song, Kwang-Seop
Yoon, Hee-Kyoon
Yoon, Ji-Sung
Abrégé
The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.
C07D 407/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07H 17/04 - Radicaux hétérocycliques contenant uniquement des atomes d'oxygène comme hétéro-atomes du cycle
DAEWOONG PHARMACEUTICAL CO., LTD. (République de Corée)
GREEN CROSS CORPORATION (République de Corée)
Inventeur(s)
Yoon, Hee-Kyoon
Park, Se-Hwan
Yoon, Ji-Sung
Choi, Soongyu
Seo, Hee Jeong
Park, Eun-Jung
Kong, Younggyu
Song, Kwang-Seop
Kim, Min Ju
Park, So Ok
Abrégé
The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.
C07D 407/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
DAEWOONG PHARMACEUTICAL CO., LTD. (République de Corée)
GREEN CROSS CORPORATION (République de Corée)
Inventeur(s)
Yoon, Hee-Kyoon
Park, Se-Hwan
Yoon, Ji-Sung
Choi, Soongyu
Seo, Hee Jeong
Park, Eun-Jung
Kong, Younggyu
Song, Kwang-Seop
Kim, Min Ju
Park, So Ok
Abrégé
The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.
C07D 407/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 409/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
PHARMACEUTICAL COMPOSITION FOR INHIBITING METASTASIS OF CANCER, COMPRISING, AS ACTIVE INGREDIENT, ANTIBODY THAT SPECIFICALLY BINDS TO EPIDERMAL GROWTH FACTOR RECEPTOR
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (République de Corée)
Inventeur(s)
Won, Jong-Hwa
Lim, Yangmi
Hur, Min-Kyu
Abrégé
The present invention provides a pharmaceutical composition for inhibiting the metastasis of cancer, comprising, as an active ingredient, an antibody that specifically binds to an epidermal growth factor receptor, and a method for inhibiting the metastasis of cancer using the composition. The composition or the method is effective in inhibiting the invasion of various gastric cancer cell lines induced by EGFR ligands. Therefore, the pharmaceutical composition can be usefully used for inhibiting the metastasis of cancer.
Kit for measuring titer of a protein comprising human Fc using indirect ELISA and method for measuring titer of a protein comprising human Fc using the same
Provided are a kit for measuring a titer of a human antibody, a humanized antibody, or a human Fc-fusion protein in human plasma or serum, and a method for measuring a titer of a human Fc-containing protein in human plasma or serum using the same, and more specifically, a kit for measuring a titer of human Fc-containing protein in human plasma or serum, the kit including a diluent for sample, a diluent for conjugate, and a cleansing solution and being used in analysis through an indirect enzyme-linked immunosorbent assay (indirect ELISA), and a method for measuring a titer of human Fc-containing protein in human plasma or serum using the same.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
